Cara Therapeutics (CARA) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Cara Therapeutics Reports Second Quarter 2015 Financial Results
August 10, 2015 4:01 PM EDTReported statistically-significant positive top-line results from Phase 2 trial for I.V. CR845 in uremic pruritus
Completed successful public offering of common stock, raising net proceeds of $75.1 million
First Pivotal trial for I.V. CR845 in acute pain on track to begin in 3Q'15
Conference call today at 4:30 p.m. ET
SHELTON, Conn., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ: CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by... More
